A Phase 3 interventional study of mRNA-1345 in Respiratory Syncytial Virus, sponsored by ModernaTX, Inc.. Completed at 11 sites in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases — none open to participants now, none under way, none of them phase 3. mRNA-1345 respiratory syncytial virus vaccine · Virus Diseases.
Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, this one is the 6th largest by enrollment, is the only one that started in 2025, is one of 4 in phase 3, and was the 10th registered.
656 studies on the registry are indexed under Virus Diseases; 83 are open to participants now.
Browse Virus Diseases studies →None of the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases is open now. The open studies under Virus Diseases, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 63 Virus Diseases studies recruiting now, 29 (46%) set no upper age limit and 22 (35%) stop at 75 or younger; 27 take children under 18; 26 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 5
First in 2020; this study’s year is marked. 1 started in 2025.
This study's enrollment of 507 is above the median of 100 across 464 interventional studies indexed under Virus Diseases.
Median enrollment 579 across the 10 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
47 studies in Virus Diseases by Moderna, Inc.: 2 open now, 6 under way, 1 of them phase 3. Of 40 finished, 17 (43%) have results posted.
Among the 47 studies in Virus Diseases by Moderna, Inc., this one is the 21st largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 in phase 3, and was the 45th registered.
Moderna, Inc.’s Virus Diseases studies by the year they started, since 2019.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, from their registry updates:
Among Moderna, Inc.’s 47 in Virus Diseases:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.
Key Inclusion Criteria:
Participants may have one or more chronic medical diagnoses, but should be medically stable as assessed by:
Key Exclusion Criteria:
Other protocol-specified inclusion and/or exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of mRNA-1345 injection administered intramuscularly on Day 1.
Biological: mRNA-1345
Suspension for injection
Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)
Time frame: Day 1 up to Day 7 (7 days post-injection)
Number of Participants with Unsolicited Adverse Events (AEs)
Time frame: Day 1 up to Day 28 (28 days post-injection)
Number of Participants with Medically Attended AEs (MAAEs), Serious AEs (SAEs), AEs of Special Interest (AESIs), and AEs Leading to Discontinuation
Time frame: Day 1 up to Day 181 (End of study)
Geometric Mean Titer (GMT) of Serum RSV-A Neutralizing Antibodies (Abs) at Day 29
Time frame: Day 29
GMT of Serum RSV-B Neutralizing Abs at Day 29
Time frame: Day 29
GMT of Serum RSV-A Neutralizing Abs
Time frame: Day 1 up to Day 181 (End of study)
Geometric Mean Fold Rise (GMFR) of Serum RSV-A Neutralizing Abs
Time frame: Day 181
GMT of Serum RSV-B Neutralizing Abs
Time frame: Day 1 up to Day 181 (End of study)
GMFR of Serum RSV-B Neutralizing Abs
Time frame: Day 181
Percentage of Participants With Seroresponse in RSV-A Neutralizing Abs
Time frame: Day 181
Percentage of Participants With Seroresponse in RSV-B Neutralizing Abs
Time frame: Day 181
Percentage of Participants With ≥2-fold Increase From Baseline in RSV-A Neutralizing Ab Titers
Time frame: Day 181
Percentage of Participants With ≥2-fold Increase From Baseline in RSV-B Neutralizing Ab Titers
Time frame: Day 181
Ran from Aug 2025 to primary completion in Mar 2026, 7 months.
Of 40 industry-sponsored phase 3 interventional studies under Virus Diseases, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 24. This study's 7 months is below that.
Counting every sponsor, half of 57 studies reached it within 14 months; a quarter within 8 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: mRNA-1345 respiratory syncytial virus vaccine